Clinical trial
A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder
NCT00491829 is registered in ClinicalTrials.gov with Sprout Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder
- Lead sponsor
- Sprout Pharmaceuticals, Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2007
- Completion date
- March 31, 2009
- Enrollment
- 945 (actual)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.